Statements (98)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:ATI-501
|
| gptkbp:acquisition |
gptkb:Viral_Clear_Pharmaceuticals
|
| gptkbp:business_model |
biotech startup
|
| gptkbp:can_lead_to |
Dr. David Boulware
|
| gptkbp:ceo |
Jean-Pierre Sommadossi
|
| gptkbp:class |
antivirals
|
| gptkbp:clinical_trial |
gptkb:United_States
gptkb:data_safety_monitoring_board gptkb:drug diverse demographics Phase 2 Phase 3 targeted therapies standard operating procedures safety and efficacy FDA review process randomized controlled trials data interpretation screening processes peer-reviewed publications quarterly reports statistical significance real-world evidence positive results patient outreach programs long-term follow-up adaptive trial designs published findings project management teams efficacy and safety data patients with COVID-19 patient health improvements regulatory submissions. |
| gptkbp:collaborations |
gptkb:Mount_Sinai_Health_System
gptkb:University_of_Minnesota gptkb:Research_Institute government agencies non-profit organizations academic institutions international organizations industry partners philanthropic foundations clinical research organizations biomedical research centers biotech partners |
| gptkbp:conference |
annual meetings
|
| gptkbp:developed_by |
innovative approaches
|
| gptkbp:discovered_by |
high-throughput screening
|
| gptkbp:focus |
antiviral therapeutics
|
| gptkbp:formulation |
optimized delivery systems
|
| gptkbp:founded |
gptkb:2013
|
| gptkbp:has_specialty |
infectious disease specialists
|
| gptkbp:headquarters |
gptkb:Borough
|
| gptkbp:healthcare |
patient-reported outcomes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Atea Pharmaceuticals
|
| gptkbp:innovation |
cutting-edge technology
RNA-based therapies |
| gptkbp:invention |
AT-527 composition
|
| gptkbp:investment |
gptkb:COVID-19
gptkb:Orbi_Med_Advisors $100 million shareholder updates |
| gptkbp:language_of_instruction |
multiple antiviral candidates
|
| gptkbp:market |
new therapies
|
| gptkbp:marketing_strategy |
global outreach
|
| gptkbp:notable_products |
AT-527
|
| gptkbp:outcome |
improved patient recovery
|
| gptkbp:partnership |
gptkb:Gilead_Sciences
gptkb:Abb_Vie pharmaceutical companies |
| gptkbp:pharmacokinetics |
gptkb:Company
multiple candidates clinical endpoints targeted approaches |
| gptkbp:publishes |
peer-reviewed journals
|
| gptkbp:receives_funding_from |
gptkb:Series_B
government grants |
| gptkbp:regulatory_compliance |
gptkb:FDA
compliance with regulations new drug application |
| gptkbp:research |
mechanism of action
novel compounds |
| gptkbp:research_areas |
gptkb:Harvard_University
infectious diseases RNA-targeted therapies |
| gptkbp:research_focus |
viral infections
|
| gptkbp:research_interest |
capital funding
|
| gptkbp:safety_record |
adverse event monitoring
|
| gptkbp:scientific_name |
experts in virology
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:student_enrollment |
clinical studies
|
| gptkbp:symbol |
AVIR
|
| gptkbp:targets |
viral RNA polymerase
|
| gptkbp:team |
experienced executives
|
| gptkbp:technology |
biopharmaceuticals
|
| gptkbp:website |
www.ateapharma.com
|